Durvalumab Boots PFS Even in Stage 3 Lung Cancer Durvalumab Boots PFS Even in Stage 3 Lung Cancer

Immunotherapy is continuing its march: the first trial of an anti-PD-L1 inhibitor in stage 3 non-small cell lung cancer has shown an impressive increase in progression-free survival.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news